We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed Inc. (RMD - Free Report) recently expanded its AirFit mask portfolio with the introduction of its first top-of-head-connected nasal CPAP mask, AirFit N30i, in the United States. The product is already available across Canada, Australia, New Zealand and most of Europe with more launches planned in other geographies, scheduled for late 2019.
AirFit N30i in Detail
This device has a top-of-head connection that keeps tubing out of the wearers’ way, letting them comfortably move and sleep in any position. Its nasal cradle cushion reduces facial markings and irritation.
Per the company, in comparison to other popular nasal top-of-head masks, three of four users preferred AirFit N30i over the traditional ones.
Market Potential
Globally, over 100 million are estimated to be afflicted with sleep apnea (per an article published in The Sleep Zone). This increasing incidence has driven demand for sleep apnea devices. Per a MarketsandMarkets report by, the global sleep apnea devices market is expecting a CAGR of 7.8% to reach $6.49 billion between 2018 and 2023.
Going by the same report, North America is projected to be the largest market for sleep apnea devices in 2018.
Rising healthcare expenditures, increasing obesity and unhealthy lifestyle practices along with expanded treatment options are anticipated to continue driving demand for sleep apnea devices. In view of this data, we believe, the latest development will help ResMed cash in on opportunities in this niche market.
Stress on Innovation
In order to maintain its leadership position in the sleep disordered breathing (SDB) market and to boost its sales base, ResMed is focusing on product development and innovation. In this regard, the company earlier unveiled its first minimal-contact full face CPAP mask — AirFit F30. Further, ResMed consistently sees a strong adoption of AirFit F20 full face mask and AirFit N20 nasal mask products globally.
Share Price Performance
Over the past year, shares of ResMed have outperformed its industry. The stock has rallied 17.5% against the industry’s decline of 3.2%.
Zacks Rank and Key Picks
ResMed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Veeva Systems (VEEV - Free Report) , Omnicell, Inc. (DXCM - Free Report) and Illumina, Inc. (ILMN - Free Report) .
Omnicell’s long-term earnings growth rate is projected at 11.8%. The stock carries a Zacks Rank #2 (Buy).
Illumina’s long-term earnings growth rate is expected at 23.4%. The stock has a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio
ResMed Inc. (RMD - Free Report) recently expanded its AirFit mask portfolio with the introduction of its first top-of-head-connected nasal CPAP mask, AirFit N30i, in the United States. The product is already available across Canada, Australia, New Zealand and most of Europe with more launches planned in other geographies, scheduled for late 2019.
AirFit N30i in Detail
This device has a top-of-head connection that keeps tubing out of the wearers’ way, letting them comfortably move and sleep in any position. Its nasal cradle cushion reduces facial markings and irritation.
Per the company, in comparison to other popular nasal top-of-head masks, three of four users preferred AirFit N30i over the traditional ones.
Market Potential
Globally, over 100 million are estimated to be afflicted with sleep apnea (per an article published in The Sleep Zone). This increasing incidence has driven demand for sleep apnea devices. Per a MarketsandMarkets report by, the global sleep apnea devices market is expecting a CAGR of 7.8% to reach $6.49 billion between 2018 and 2023.
Going by the same report, North America is projected to be the largest market for sleep apnea devices in 2018.
Rising healthcare expenditures, increasing obesity and unhealthy lifestyle practices along with expanded treatment options are anticipated to continue driving demand for sleep apnea devices. In view of this data, we believe, the latest development will help ResMed cash in on opportunities in this niche market.
Stress on Innovation
In order to maintain its leadership position in the sleep disordered breathing (SDB) market and to boost its sales base, ResMed is focusing on product development and innovation. In this regard, the company earlier unveiled its first minimal-contact full face CPAP mask — AirFit F30. Further, ResMed consistently sees a strong adoption of AirFit F20 full face mask and AirFit N20 nasal mask products globally.
Share Price Performance
Over the past year, shares of ResMed have outperformed its industry. The stock has rallied 17.5% against the industry’s decline of 3.2%.
Zacks Rank and Key Picks
ResMed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Veeva Systems (VEEV - Free Report) , Omnicell, Inc. (DXCM - Free Report) and Illumina, Inc. (ILMN - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Omnicell’s long-term earnings growth rate is projected at 11.8%. The stock carries a Zacks Rank #2 (Buy).
Illumina’s long-term earnings growth rate is expected at 23.4%. The stock has a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>